Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Saved in:
Bibliographic Details
Title: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Authors: Viale, G.1, Regan, M. M.2, Dell'Orto, P.1, Mastropasqua, M. G.1, Maiorano, E.3, Rasmussen, B. B.4, MacGrogan, G.5, Forbes, J. F.6, Paridaens, R. J.7, Colleoni, M.8, Láng, I.9, Thürlimann, B.10, Mouridsen, H.11, Mauriac, L.12, Gelber, R. D.2, Price, K. N.2, Goldhirsch, A.8,13, Gusterson, B. A.14, Coates, A. S.15
Source: Annals of Oncology. Oct2011, Vol. 22 Issue 10, p2201-2207. 7p.
Database: Academic Search Ultimate
Description
ISSN:09237534